Screening for Inhibitors of Tau Polymerization

Marcus      Pickhardt; Martin   von   Bergen; Zuzana      Gazova; Antje      Hascher; Jacek      Biernat; Eva-Maria      Mandelkow; Eckhard      Mandelkow

doi:10.2174/1567205053585891

Abstract

The histopathological diagnosis of Alzheimers disease relies on two kinds of proteinaceous aggregates: the extracellular plaques built from filaments of the Aβ-peptide and the intracellular tangles consisting of tau polymerized into Paired Helical Filaments (PHFs). The order of aggregation events is still under debate, but it is well accepted that taurelated changes have an important impact on the viability of neurons. In neurons, early morphological changes are seen in axons which begin to loose and retract synapses. This process is accompanied by an increase of aggregated tau protein. Thus the prevention of tau aggregation seems to be a valuable target for therapy of Alzheimers disease. Here we present a screening procedure by which we identified inhibitors of tau polymerization. In the primary screen we used a thioflavin-S based assay which detects PHF formation in solution. These initial hits were further analyzed for their capacity to depolymerize preformed PHFs. These results were confirmed by several secondary assays (tryptophan fluorescence, pelleting, filter trapping and electron microscopy). By this approach it is possible to identify small molecule compounds which prevent or reverse the aggregation of tau and thereby might improve the viability of neurons in a therapeutic approach.

Keywords: alzheimer, ’, s disease, neurodegenerative diseases, paired helical filaments (phfs), phosphorylation, posttranslational changes, huntington, spectroscopy, filter trapping assay